Skip to main content
Caplight Logo









Genome Biologics

Genome Biologics

Private
FrankfurtHealthcare & Life Scienceshttps://genomebiologics.com/

Last Round

VC Round

Dec 20, 2021

Total Funding Raised

$3.01M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

Genome Biologics is a biotechnology company that provides human cardiac organoid services for drug discovery, cardiac safety pharmacology, and disease modeling.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting, Government Contracts

AI Layer

Application

Keywords

human cardiac organoidscontract research organizationCROcardiotoxicity screeningorganoid platformdrug discovery servicescardiovascular disease modelingalternative to animal testing3D cell cultureiPSC-derived organoidsheart-in-a-dishmulti-omics profilingcardiac safety pharmacologypredictive toxicologypreclinical studiesnew approach methodologiesNAMsAI-augmented drug discovery

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Genome Biologics Comparables

Compare Genome Biologics with similar companies based on industry and business-model similarity.

Genome Biologics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
HeartBeat.bio AG
90%
Ncardia
83%
Dynomics
82%

Genome Biologics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
VC RoundDec 20, 2021
GrantSep 1, 2018

Genome Biologics Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Aug 21, 2026

    Monthly visitors increased 39% MoM.

  • Jan 20, 2026

    Monthly visitors increased 1527% MoM.

Genome Biologics Filings

Explore SEC and related filing metadata, where available.

Genome Biologics filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Genome Biologics's valuation, stock price, and market status.

Is Genome Biologics a public or private company?

Genome Biologics is a private company.

What is the current stock price of Genome Biologics?

Genome Biologics is a private company with no public stock price. No recent secondary market data is available.

How much is Genome Biologics worth (valuation)?

Valuation information for Genome Biologics is not publicly available.

Can I buy Genome Biologics stock?

Genome Biologics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Genome Biologics's last funding round?

Genome Biologics's most recent funding round was VC Round on December 20, 2021.

Who are the main investors in Genome Biologics?

Key investors in Genome Biologics include Horizon 2020, European Innovation Council, Johnson & Johnson Innovation - JLABS.

Will Genome Biologics IPO soon?

No public IPO plans have been announced for Genome Biologics.

How can I track Genome Biologics secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Genome Biologics's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersFrankfurt
Employee Range4
Year Founded2016
Last FundingDec 20, 2021

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?